{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T17:28:02Z","timestamp":1778434082893,"version":"3.51.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"Objective<\/jats:title>Dual pathway inhibition (DPI) by combining acetylsalicylic acid (ASA) with low-dose rivaroxaban has been shown to reduce cardiovascular events in patients with peripheral arterial disease (PAD) when compared to ASA monotherapy. A potential explanation is that inhibition of factor Xa improves endothelial function through crosstalk between coagulation and inflammatory pathways, subsequently attenuating the occurrence of cardiovascular events. We hypothesize that the addition of rivaroxaban to ASA in PAD patients leads to improved endothelial function.<\/jats:p><\/jats:sec>Design<\/jats:title>An investigator-initiated, multicentre trial investigating the effect of DPI on endothelial function.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients, diagnosed with PAD, were enrolled in two cohorts: cohort A (Rutherford I-III) and cohort B (Rutherford IV-VI). Participants received ASA monotherapy for a 4-weeks run-in period, followed by 12 weeks of DPI. Macro- and microvascular endothelial dysfunction were studied by measuring carotid artery reactivity upon sympathetic stimulus and by measuring plasma endothelin-1 concentrations, respectively. All measurements were performed during the use of ASA (baseline) and after 12 weeks of DPI.<\/jats:p><\/jats:sec>Results<\/jats:title>159 PAD patients (111 cohort A, 48 cohort B) were enrolled. Twenty patients discontinued study drugs early. Carotid artery constriction upon sympathetic stimulation at baseline (ASA) and after 12 weeks of DPI was similar in the total group, 22.0 vs. 22.7% (p<\/jats:italic> = 1.000), and in the subgroups (Cohort A 22.6 vs. 23.7%, p<\/jats:italic> = 1.000; cohort B 20.5 vs. 20.5%, p<\/jats:italic> = 1.000), respectively. The mean concentration of plasma endothelin-1 at baseline and after 12 weeks of DPI did not differ, 1.70 \u00b1 0.5 vs. 1.66 \u00b1 0.64 pmol\/L (p<\/jats:italic> = 0.4<\/jats:italic>40) in the total group, 1.69 \u00b1 0.59 vs. 1.62 \u00b1 0.55 pmol\/L in cohort A (p<\/jats:italic> = 0.202), and 1.73 \u00b1 0.53 vs. 1.77 \u00b1 0.82 pmol\/L in cohort B (p<\/jats:italic> = 0.6<\/jats:italic>82), respectively.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Macro- and microvascular endothelial dysfunction, as reflected by carotid artery reactivity and plasma endothelin-1 concentrations, are not influenced in PAD patients by addition of low-dose rivaroxaban to ASA monotherapy for 12 weeks.<\/jats:p><\/jats:sec>Trial registration<\/jats:title>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04218656<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.979819","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:21:37Z","timestamp":1665069697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial"],"prefix":"10.3389","volume":"9","author":[{"given":"Loes H.","family":"Willems","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick H. J.","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo A.","family":"Groh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina I.","family":"Kooijman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Ten Cate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri M. H.","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Rogier T.","family":"Donders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozemarijn J.","family":"van der Vijver-Coppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdolna","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel M. P. J.","family":"Reijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel C.","family":"Warl\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"REACH Registry Investigators. one-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"REACH Registry investigators. comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1161\/CIR.0000000000000501","article-title":"AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"n Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a modulator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"n Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/TH13-09-0730","article-title":"Targeting factor Xa and thrombin: impact on coagulation and beyond","volume":"111","author":"Esmon","year":"2014","journal-title":"Thromb Haemost."},{"key":"B10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/01.CIR.0000153339.27064.14","article-title":"Endothelial function: cardiac events","volume":"111","author":"Lerman","year":"2005","journal-title":"Circulation."},{"key":"B11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.amjcard.2013.08.051","article-title":"Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease","volume":"113","author":"Shechter","year":"2014","journal-title":"Am J Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJM199007053230105","article-title":"Epstein Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension","volume":"323","author":"Panza","year":"1990","journal-title":"n Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1161\/01.CIR.88.6.2541","article-title":"The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients","volume":"88","author":"Casino","year":"1993","journal-title":"Circulation."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1161\/01.CIR.94.6.1276","article-title":"Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus","volume":"94","author":"M\u00e4kimattila","year":"1996","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0735-1097(94)90305-0","article-title":"Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women","volume":"24","author":"Celermajer","year":"1994","journal-title":"J Am Coll Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/01.ATV.0000051384.43104.FC","article-title":"Endothelial dysfunction: a marker of atherosclerotic risk","volume":"23","author":"Bonetti","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","article-title":"Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease","volume":"101","author":"Sch\u00e4chinger","year":"2000","journal-title":"Circulation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/01.CIR.104.2.191","article-title":"Prognostic significance of endothelial dysfunction in hypertensive patients","volume":"104","author":"Perticone","year":"2001","journal-title":"Circulation."},{"key":"B19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJM200002173420702","article-title":"Effect of exercise on coronary endothelial function in patients with coronary artery disease","volume":"342","author":"Hambrecht","year":"2000","journal-title":"n Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM199502233320801","article-title":"Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease","volume":"332","author":"Treasure","year":"1995","journal-title":"n Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cjca.2018.10.015","article-title":"Carotid artery function is restored in subjects with elevated cardiovascular disease risk after a 12-week physical activity intervention","volume":"35","author":"Buckley","year":"2019","journal-title":"Can J Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/SLA.0000000000002558","article-title":"Carotid artery reactivity predicts events in peripheral arterial disease patients","volume":"269","author":"Van Mil","year":"2019","journal-title":"Ann Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/HJH.0000000000001274","article-title":"Correlation of carotid artery reactivity with cardiovascular risk factors and coronary artery vasodilator responses in asymptomatic, healthy volunteers","volume":"35","author":"van Mil","year":"2017","journal-title":"J Hypertens."},{"key":"B24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/hrt.74.6.620","article-title":"Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms","volume":"74","author":"Kaski","year":"1995","journal-title":"Br Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature."},{"key":"B26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00380-020-01767-x","article-title":"Elevated serum endothelin-1 is an independent predictor of coronary microvascular dysfunction in non-obstructive territories in patients with coronary artery disease","volume":"36","author":"Naya","year":"2021","journal-title":"Heart Vessels."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0163","DOI":"10.1097\/MD9.0000000000000163","article-title":"A protocol for DUAL pathway inhibition (low-dose rivaroxaban and aspirin) as compared to aspirin only to improve endothelial function in peripheral artery disease","volume":"2","author":"Willems","year":"2021","journal-title":"Med Case Rep Study Protocols."},{"key":"B28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for reports dealing with lower extremity ischemia: revised version","volume":"26","author":"Rutherford","year":"1997","journal-title":"J Vasc Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1111\/j.1538-7836.2007.02687.x","article-title":"The plasma kallikrein-kinin system and risk of cardiovascular disease in men","volume":"5","author":"Govers-Riemslag","year":"2007","journal-title":"J Thromb Haemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJM198610233151702","article-title":"Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries","volume":"315","author":"Ludmer","year":"1986","journal-title":"n Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/01.CIR.80.3.458","article-title":"Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans","volume":"80","author":"Cox","year":"1989","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"542567","DOI":"10.3389\/fmed.2020.542567","article-title":"Overview of the Assessment of endothelial function in humans","volume":"7","author":"Chia","year":"2020","journal-title":"Front Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(95)91322-X","article-title":"Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication","volume":"346","author":"Stroes","year":"1995","journal-title":"Lancet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","article-title":"Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month","volume":"95","author":"O'Driscoll","year":"1997","journal-title":"Circulation."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e034580","DOI":"10.1136\/bmjopen-2019-034580","article-title":"Pragmatic evaluation of a coproduced physical activity referral scheme: a UK quasi-experimental study","volume":"10","author":"Buckley","year":"2020","journal-title":"BMJ Open."},{"key":"B36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"253","author":"Gailani","year":"1991","journal-title":"Science."},{"key":"B37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Warfarin Antiplatelet Vascular Evaluation Trial","year":"2007","journal-title":"n Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1161\/CIRCRESAHA.119.315099","article-title":"Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1","volume":"126","author":"Petzold","year":"2020","journal-title":"Circ Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"865166","DOI":"10.3389\/fcvm.2022.865166","article-title":"Differential inhibition of platelet reactivity by dual therapy with aspirin and low-dose rivaroxaban in peripheral arterial disease: a pilot study","volume":"9","author":"Jurk","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","volume":"242","author":"Hara","year":"2015","journal-title":"Atherosclerosis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1172\/JCI113276","article-title":"Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis","volume":"80","author":"Harrison","year":"1987","journal-title":"J Clin Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1038\/s41598-019-40602-w","article-title":"Targeting coagulation factor Xa promotes regression of advanced atherosclerosis in apolipoprotein-e deficient mice","volume":"9","author":"Posthuma","year":"2019","journal-title":"Sci Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.thromres.2021.11.027","article-title":"Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19","volume":"209","author":"Willems","year":"2022","journal-title":"Thromb Res."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.979819\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:21:42Z","timestamp":1665069702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.979819\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":43,"alternative-id":["10.3389\/fcvm.2022.979819"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.979819","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"979819"}}